Viz.ai Solutions for Cerebral Aneurysm and AAA Detection Evaluated in Real-World Studies

December 3, 2024—Viz.ai announced new clinical data showing positive outcomes with real-world impact of the company’s technology in clinical practice for treatment of patients with cerebral aneurysms or abdominal aortic aneurysms (AAAs).

The studies are being presented at RSNA 2024, the Radiologic Society of North America’s annual scientific session held December 1-5 in Chicago, Illinois.

According to Viz.ai, the first study, “Performance and Validation of a Machine Learning-Based Aneurysm Detection Tool in the Clinical Setting,” assessed the performance of Viz Aneurysm through a retrospective evaluation of 703 head CTA exams from UC Irvine Health System in Orange, California.

The company reported that the Viz Aneurysm algorithm detected positive aneurysm cases with a sensitivity of 96.6% and specificity of 98.1%. The overall positive predictive value of Viz Aneurysm in this study was 82.4% and the negative predictive value was 99.7%.

Additionally, eight cases were detected with multiple aneurysms and 21 cases with aneurysms < 4 mm, suggesting Viz Aneurysm may be used to detect and manage patients with a lower risk of rupture, noted Viz.ai.

“Our findings show that the Viz Aneurysm algorithm successfully detected most of the aneurysms in our clinical dataset and performed consistently across subset analyses,” commented Jennifer E. Soun, MD, in the company’s press release. “Viz Aneurysm’s high accuracy shows its potential use to help detect and manage aneurysms in patients.” Dr. Soun is an assistant professor, radiological services and neurology at University of California, Irvine School of Medicine in Irvine, California.

Viz.ai stated that the second study, “Performance of AAA AI Triage Software on Real-World Patient Data,” evaluated the performance of the Viz AAA algorithm across 341 CTA exams of the abdomen from Montefiore Health System in New York, New York.

In this retrospective analysis, the Viz AAA algorithm detected positive aneurysm cases with a sensitivity > 85%, whether cases with graft repair were included (86.5%) or not (88.6%), and specificity of 98.3%. Additionally, the investigators noted that 25 CTAs with AAA and graft repair were correctly identified as positive by the Viz AAA module, stated the company.

“These data suggest that this AI-triage tool is both highly sensitive and specific, indicating high reliability for cases determined as positive across our diverse patient scans,” commented Matthew Lazarus, MD, in the Viz.ai press release. “We believe incorporation of Viz AAA may help radiologists and other clinicians positively identify patients with AAA and potentially facilitate optimal treatment, management, and health outcomes.” Dr. Lazarus is an assistant professor of radiology at Montefiore Medical Center and Albert Einstein College of Medicine in New York, New York.